Skip to main content
. 2018 Feb 22;20(3):280–288. doi: 10.1016/j.neo.2018.01.007

Table 1.

Characteristics of the Study Group

n (%)
Total pairs 113 (100%)
Age
 <60 years 76 (67.3)
 >60 years 37 (32.7)
 Median 55 years
FIGO stage primary
 FIGO I 2 (1.8)
 FIGO II 6 (5.3)
 FIGO III 93 (82.3)
 FIGO IV 12 (10.6)
Recurrence used for IHC
 1st 98 (86.7)
 2nd 6 (5.3)
 3rd 7 (6.2)
 Other 2 (1.8)
Postoperative residual tumor
 None 79 (69.9)
 Any 34 (30.1)
First-line chemotherapy
 Taxol/carboplatin 88 (77.9)
 Other platinum-based 19 (16.8)
 Other 6 (5.3)
Platinum sensitivity status after 1st-line treatment
 Sensitive 89 (78.8)
 Resistant 16 (14.2)
 Missing 8
Platinum sensitivity status after 2nd-line treatmenta
 Sensitive 58 (84.1)
 Resistant 11 (15.9)
 Missing 29
BRCA germline status
 wt 12 (57.1)
 BRCA1 mt 7 (33.3)
 BRCA2 mt 2 (9.5)
 Missing 94
BRCA tumor status (includes germline and somatic mt)b
 wt 31 (58.5)
 BRCA1 mt 16 (30.2)
 BRCA2 mt 6 (11.3)
 Missing 60
a

First recurrence only

b

BRCA status in tumor tissue was identical in all pairs of primary and recurrent tumors.